Drug profile · INN
lanreotide acetate
SOMATULINE DEPOT
lanreotide acetate (SOMATULINE DEPOT) is a somatostatin receptor 5 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — lanreotide acetate
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
lanreotide acetate (SOMATULINE DEPOT) is a somatostatin receptor 5 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Somatostatin receptor 5 agonist
Primary target: Somatostatin receptor type 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lanreotide acetate?
lanreotide acetate (SOMATULINE DEPOT) is a somatostatin receptor 5 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for lanreotide acetate?
SOMATULINE DEPOT is a marketed brand name for lanreotide acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lanreotide acetate?
lanreotide acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.